CD274 and head and neck squamous cell carcinoma: These findings suggest that targeting the PI3Kγ and PD-L1 pathways concurrently could represent a promising therapeutic approach for improving immunotherapy outcomes in HNSCC, potentially overcoming the immunosuppressive barriers that limit current treatment strategies.